Jonathan Fillmore, MD
Endocrinology, Diabetes & Metabolism · Trumbull, CTNPI 1578592713
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 809 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 45 manufacturers reported payments, led by Novo Nordisk at 27.8% of the total. Reporting peaked in 2023 at $2,997 and has fallen 64.6% since, to $1,061 in 2025.
Across 809 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Lilly USA, LLC$1K
- Xeris Pharmaceuticals, Inc.$877
- Valeritas, Inc.$758
- Abbott$678
- Amgen$551
- plus $4K from 39 others
What the payments were for
- Speaking & faculty fees$7506%
- Travel & lodging$80%
- Food & beverage$11,08493%
- Education$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,907 in reported general payments places this provider in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 623 | $859,787 |
| TrulicityDulaglutide | 175 | $290,631 |
| MounjaroTirzepatide | 198 | $252,004 |
| JardianceEmpagliflozin | 223 | $243,702 |
| Tresiba Flextouch U-200Insulin Degludec | 144 | $191,359 |
| ProliaDenosumab | 100 | $176,777 |
| Tresiba Flextouch U-100Insulin Degludec | 151 | $110,135 |
| GenotropinSomatropin | 16 | $98,830 |
| FarxigaDapagliflozin Propanediol | 58 | $79,775 |
| RybelsusSemaglutide | 36 | $73,979 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 24 | $61,243 |
| JanuviaSitagliptin Phosphate | 28 | $43,275 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 292 | $42,696 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 66 | $38,332 |
| Humulin R U-500Insulin Regular, Human | 19 | $33,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $3,311 | $933,766659 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog Mix 75-25, Humalog | $1,391 | $554,832407 claims |
| Boehringer IngelheimJardiance | $535 | $243,702223 claims |
| AmgenProlia | $551 | $176,777100 claims |
| MerckJanuvia, Janumet Xr, Janumet | $58 | $91,22473 claims |
| AstraZenecaFarxiga | $106 | $79,77558 claims |
| Johnson & JohnsonInvokana | $30 | $24,69718 claims |
| AbbVieSynthroid | $350 | $21,943208 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $316 | $16,71011 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $86 | $6,971725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Trumbull
- Glenn RichTrumbull$210K
- Judith CastilloTrumbull$37K
- Joseph RosaTrumbull$8K
- Agnieszka GrochowalskaTrumbull$8K
- Erika StrohmayerTrumbull$4K
- Linda WernerTrumbull$3K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.